










Presentation 9-month Financial Report


13 October 2011

WILEX today: Broad portfolio and strong partners

Product	Technology	Indication	Research	Pre-clinical	Clinical development			Market	Partner	
					Phase I	Phase II	Phase III			
REDECTANE®	Antibody (diagnostic)	Renal mass	→						 (ww**)	
RENCAREX®	Antibody (therapeutic)	non-metast. ccRCC*	→						 (Southern Europe)  PROMETHEUS® (USA) Therapeutics & Diagnostics	
MESUPRON®	uPA inhibitor	Pancreatic cancer	→							
		Breast cancer	→							
WX-554	MEK inhibitor	Cancer	→						 (ww)	
WX-037	MEK inhibitor	Cancer	→						 (ww)	
2 Antibodies		Cancer	→						 (ww)	
ADC Platform	Antibody drug conjugates	Cancer	→						WILEX Group	
Diagnostic tests	ELISA/IHC	HER-2, CAIX, uPA, PAI-1, EGFr; VEGF etc.	→							 WILEX Group

*clear cell Renal Cell Carcinoma, non-metastatic, ** worldwide

→ Revenue realisation at WILEX




Rx	RENCAREX®	✓ Interim analysis for efficacy process started
	MESUPRON®	✓ US commercialisation rights to Prometheus Laboratories Inc.
	WX-554 /WX-037	✓ Fast track designation from FDA
Dx	REDECTANE®	✓ Patient recruitment Phase II breast cancer trial completed
	In-vitro diagnostics	✓ Phase I with oral WX-554 in healthy volunteers started
Cx	ADC + CSR	✓ Pre-clinical development (GMP and toxicity studies) for WX-037
		✓ Pre-BLA Meeting with FDA
		✓ Design of an outcome based study and next meeting with FDA prepared
		✓ WILEX Inc. ISO certification
		✓ US marketing and distribution agreement with ALPCO
		✓ Integration of Heidelberg Pharma into the Group completed
		✓ Material Transfer Agreements with third companies for ADC




Financial review 9M 2011

Sales revenue and other income 9M 2011

*€ m ; rounded





*€ m ; rounded




- Income more than quadrupled
- Sales revenue came to € 4.7 million (previous year: € 0 million)
- Other income lower than previous year
 - Prepayments accrued and recognised in line with project progress
- Employees increased to 119 (31 August 2010: 72)

Operating expenses 9M 2011

*€ m; rounded




*€ m; rounded




- Operating expenses comparable to previous year
- R&D expenses 74 % of total costs
 - 9.9% lower than in 9M 2010
- Administrative costs € 600k higher due to acquisition
- Net loss for the period lower than previous year, improvement of 23.2 %
- EPS of € -0.65 improved (Q1 2010: € -1.06)

Segment reporting 9M 2011

*€ m ; rounded




*€ m ; rounded




- Revenue in Rx related to Prometheus
- Sales revenue related to WILEX Inc. in Dx
- Cx revenue increased
- Internal sales revenue of € 0.3 million
- Costs of REDECTANE® in the Dx segment included

Balance sheet as of 31 August 2011


*€ m; rounded



*€ m; rounded



*€ m; rounded



- Total assets amounted to € 32.4 m (previous year: € 5.6 m)
- Cash balance with € 8.1 m higher than previous year (€ 1.9 m)
- Cash usage per month fell to € 1.9 m (9M 2010: € 2.1 m)
- Equity improved to € 4.6 m (31.11.2010: € -1.30 m)
 - Acquisition Heidelberg Pharma – preliminary values



Guidance 2011


In € m	Results 2010	Guidance 2011
Sales revenue & other income	1.3	9.0 – 11.0
Operating expenses	24.4	26.0 – 30.0
Operating result	(23.1)	(16.0) – (20.0)
Total funding requirement	25.5	24.0 – 27.5
Funds required per month	2.06	2.0 – 2.3

- **Adjusted financial guidance from July 2011 still applies**
- **Guidance comprises WILEX AG, WILEX Inc. and Heidelberg Pharma AG**

Rx	RENCAREX®	<ul style="list-style-type: none">→ Interim analysis for efficacy, IDMC recommendation Q4 2011→ Decision: product or \$15m / \$20m cash from Prometheus agreement
	MESUPRON®	<ul style="list-style-type: none">→ Data breast cancer Phase II trial expected 2012
	WX-554	<ul style="list-style-type: none">→ Data Phase I in healthy volunteers (oral) expected Q1 2012→ Start Phase I in cancer patients (oral) expected early 2012
Dx	REDECTANE®	<ul style="list-style-type: none">→ Further discussions with FDA regarding outcome based study and approval process
	In-vitro diagnostics	<ul style="list-style-type: none">→ Increase marketing activities and revenue
Cx	ADC + CSR	<ul style="list-style-type: none">→ Third-party ADC collaborations→ Increase sales revenue

WILEX is well positioned

- Oncology-focused biopharmaceutical company
- Transition from R&D to commercially driven business
- Product candidates with strong competitive profiles
- Important clinical and commercial milestones in the next months
- Integrative approach through combination of therapeutics and diagnostics



Therapeutics (Rx) + Diagnostics (Dx) + Customer Specific Research (Cx)

- 23 February 2012 Annual Report 2011, Financial press conference and analysts' meeting
- 12 April 2012 3-month Financial Report 2012
- 25 May 2012 Annual General Meeting 2012
- 12 July 2012 Half-yearly Financial Report 2012
- 11 October 2012 9-month Financial Report 2012

Forward looking statements

This communication contains certain forward-looking statements, relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by general discussion of strategy, plans or intentions of the Company. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: uncertainties related to results of our clinical trials, the uncertainty of regulatory approval and commercial uncertainty, reimbursement and drug price uncertainty, the absence of sales and marketing experience and limited manufacturing capabilities, attraction and retention of technologically skilled employees, dependence on licenses, patents and proprietary technology, dependence upon collaborators, future capital needs and the uncertainty of additional funding, risks of product liability and limitations of insurance, limitations of supplies, competition from other biopharmaceutical, chemical and pharmaceutical companies, environmental, health and safety matters, availability of licensing arrangements, currency fluctuations, adverse changes in governmental rules and fiscal policies, civil unrest, acts of God, acts of war, and other factors referenced in this communication.

Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

This material is not intended as an offer or solicitation for the purchase or sale of shares of WILEX AG. This material may not be distributed within countries where it may violate applicable law.

WILEX AG

Grillparzerstr. 10
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-0
Fax: +49 (0)89-41 31 38-99
Website: www.wilex.com

Corporate Communications

Katja Arnold (CIRO)
Email: [investors\[at\]wilex.com](mailto:investors[at]wilex.com)
Tel.: +49 (0)89-41 31 38-126

ISIN: DE0006614720
Symbol: WL6
Reuters: WL6G.DE
Bloomberg: WL6G.GR